Senti Biosciences jumps as BofA starts coverage with "buy"

Senti Biosciences Holdings

29/09/2022 18:11

** Senti Biosciences Inc's shares  SNTI.O  rise 50% to $2.11
as BofA initiates coverage of the gene therapy developer with
"buy" on the potential of co's drug development platform
    ** Stock set for biggest one-day pct gain in two months
    ** Brokerage sets PT at $7, which is 5x stock's last close;
says co's platform shows potential to attack new cancer targets
with fewer limitations compared to current approaches
    ** Sees potential in co's current drug development
partnerships, including with Roche  ROG.S  unit Spark
Therapeutics, and says they could provide meaningful upside in
the future
    ** Brokerage believes broad applicability of co's platform
across cell and gene therapy creates opportunities for
additional partnerships
    ** Charden Capital had initiated coverage of the co earlier
this week  with a "buy" rating  urn:newsml:reuters.com:*:nL4N30U2AJ
    ** Including the session's gains, stock has fallen 79% YTD
 (Reporting by Shristi  Achar A)
 ((Shristi.AcharA@thomsonreuters.com;))